



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Some of the content from retired medical policy 00699 Light Therapy for Vitiligo is included in medical policy 00131 Ultraviolet Light Therapy Delivery Devices for Home Use.

Note: Dermatologic Applications of Photodynamic Therapy is addressed separately in medical policy 00098.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider an in-home Ultraviolet B (UVB) light therapy delivery device to be **eligible for coverage**.**

Patient Selection Criteria

Coverage eligibility for an in-home Ultraviolet B (UVB) light therapy delivery device may be considered when **ALL** of the following criteria are met:

- The treatment is for **ONE** of the following conditions:
 - Atopic dermatitis, when topical treatment alone has failed; **OR**
 - Pityriasis lichenoides; **OR**
 - Pruritus of hepatic disease; **OR**
 - Pruritus of renal failure; **OR**
 - Psoriasis, when topical treatment alone has failed; **OR**
 - Cutaneous T-cell lymphoma including mycosis fungoides and Sézary syndrome;

AND

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

- The treatment meets **ALL** of the following criteria:
 - Treatment is conducted under a physician's supervision with regularly scheduled exams; **AND**
 - Treatment is expected to be long term (3 months or longer); **AND**
 - The individual meets **ANY** of the following:
 - The individual is unable to attend office-based therapy due to a serious medical or physical condition (for example, confined to the home, leaving home requires special services or involves unreasonable risk); **OR**
 - Office-based therapy has failed to control the disease and it is likely that home-based therapy will be successful; **OR**
 - The individual suffers from severe psoriasis with a history of frequent flares which require immediate treatment to control the disease.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers home ultraviolet light therapy using ultraviolet A (UVA) light devices for all indications to be **investigational**.*

The use of an in-home Ultraviolet B (UVB) delivery device when patient selection criteria are not met, including but not limited to vitiligo, is considered to be **investigational**.*

Background/Overview

Description of UV Light Therapy

UV light therapy is an established treatment for skin disorders that uses UV light alone, or in combination, with topical preparations or oral medications. UV therapy involves exposure of the individual's skin to ultraviolet A (UVA) or ultraviolet B (UVB) radiation using a specialized light source. As an alternative to UV therapy alone, some individuals respond to the Goeckerman or modified Goeckerman treatment, which is comprised of coal tar dressings in combination with exposure to UVB light.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

UVB light can be categorized as wide-band (or broad-band) and narrow-band, which refers to the range of wavelengths included in the UV light source. The wide-band devices deliver full spectrum UVB light. The narrow-band devices deliver a very narrow range of the UV light spectrum, focusing on the specific wavelengths most effective for the treatment of disease. Narrow-band UVB (NB-UVB) light can be delivered with either a light bulb or with a hand-held laser device. UVB treatment is typically offered using a light “booth” or “light box” several times a week for as long as the condition persists, which may be for the lifetime of the individual. In most cases an individual must go to a doctor’s office or other facility for treatments. However, UVB treatment is available for home use under certain circumstances and under strict physician supervision.

UVA light is offered in conjunction with a photosensitizer called psoralen, and this combined approach may be referred to as photochemotherapy. Photosensitizers can be applied directly to the skin or taken orally and make the skin more sensitive to ultraviolet light. Photochemotherapy is used for more severe cases of skin diseases that fail to respond to topical therapy. One type of photochemotherapy known as PUVA (Psoralen with UVA) involves the topical or oral administration of psoralen (a potent photosensitizing drug), followed by exposure to varying doses of UVA light. The use of drugs and the higher risk of adverse reactions, including a higher risk of skin cancer, have generally limited PUVA therapy to the office setting.

However, the use of UVA and UVB light therapy carries a significant risk of sunburn and increased skin cancer risk. The supervision of a physician is needed to make sure that the dose of UV light delivered to the treatment area is in the therapeutic range but does not exceed safe levels. Skin cancer, skin typing or phototesting is usually performed prior to treatment to determine the appropriate radiation dose. While high doses of UV light may result in faster clearing of the lesions, the normal skin surrounding lesions cannot tolerate such exposure and the risk of skin cancer is increased. Multiple sessions over 3 or more months are often required to produce clearing of skin lesions. During UV light therapy, individuals need regular medical assessments to evaluate the effectiveness of the therapy and to monitor for the development of side effects such as “sun burn” and pruritus (itching), skin cancer, photoaging, and liver or kidney disease.

UVB home therapy devices

The majority of individuals undergoing UV treatment can be treated in the office. However, some individuals require treatments at a frequency that makes office visits overly burdensome. Home therapy with UVB light is an alternative. Concerns regarding over-exposure to unsafe levels of UVB

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

radiation in the home setting have been addressed with the evolution of integrated security features such as keys, pass codes, etc. As with UVB therapy performed in the office, routine clinical evaluation should be conducted on home therapy individuals to ensure that exposure is kept to the minimum level compatible with adequate control of disease and the prevention of complications.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Atopic dermatitis (AD)

The initial treatment of AD typically consists of topical and non-pharmacological therapies as well as modifications in individual environments or occupations. Phototherapy is limited to those whose symptoms are not adequately controlled by the initial treatment modalities. There are numerous treatment protocols, but in general, individuals are dosed according to their minimal erythema dose and/or Fitzpatrick skin type. The AAD (2014) notes “Phototherapy can be administered on a scheduled but intermittent basis over time, or more continuously as maintenance therapy, for patients with refractory or chronic disease.”

Cutaneous T-cell lymphoma (CTCL)

Non-Hodgkin lymphoma includes two types of cutaneous lymphomas, T-cell lymphomas (CTCLs) and B-cell lymphomas (CBCLs), with CTCLs accounting for the majority of cutaneous lymphomas. According to the National Comprehensive Cancer Network^{®†} (NCCN) Clinical Practice Guidelines (CPGs) in Oncology^{®‡} for Primary Cutaneous Lymphomas, Mycosis Fungoides (MF) accounts for 50% to 70% of CTCL cases and Sézary syndrome (SS) accounts for less than 5% of CTCL cases (2023). MF is considered an indolent malignancy and generally is associated with a slow progression while the median survival of SS is only 32 months from diagnosis (Trautinger, 2006). While CTCLs develop in the skin, the disease can progress and involve other areas such as lymph nodes, blood or visceral organs. Prognosis and treatment are dependent upon several factors including, but not limited to extent and type of skin involvement, overall stage, whether extracutaneous disease is present and peripheral blood involvement (NCCN, 2023).

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

Mycosis Fungoides and Sézary syndrome

Ultraviolet light therapy is an established treatment of MF and therapies have included UVB (broad-band and narrow-band) and UVA treatments (Hodak, 2015). Phototherapy can be used at various stages of MF, either alone or in combination with systemic therapy (Hodak, 2015). The 2023 NCCN CPGs for Primary Cutaneous Lymphomas include a 2A indication for UVB therapy for patch/thin plaques in MF/SS with limited/localized or generalized skin involvement. In addition, NCCN includes a 2A indication for UVB in stage III MF/SS, noting that while generalized skin directed therapies may not be well tolerated in this population, phototherapy can be used successfully.

Due to the low incidence of MF, there is a dearth of appropriately powered randomized controlled trials (RCTs) and most recommendations are generally based upon small studies, case series or expert opinion. Olsen and colleagues reported on the results of three studies which included home broad-based UVB therapy which consisted of a total of 109 individuals who presented with stage 1A or 1B MF. Home treatments included daily phototherapy while office-based treatments were carried out 3 times per week. A total of 58 individuals received home-based therapy, with 48 of these 58 individuals receiving only home-based therapy and the remaining 10 individuals receiving home therapy after office-based therapy. The authors noted that maintenance regimens within the studies varied and likely affected response duration. Relapse was uncommon while individuals were on maintenance phototherapy (2/18), but was more common once maintenance phototherapy was discontinued (12/23). The authors found that individuals using home-based phototherapy were much more likely to continue maintenance phototherapy than individuals who received office-based phototherapy.

Pityriasis lichenoides

UVB has also been recommended as a treatment for several other conditions. Pityriasis lichenoides is a rare collection of skin disorders that have been reported to progress to cutaneous lymphoma or an ulceronecrotic presentation, both of which carry a significant risk of mortality. Treatment is difficult and aggressive approaches are usually recommended. According to one source, the use of UVB phototherapy has been the most successful treatment method and is considered first-line therapy (Khachemoune, 2007).

Pruritus of hepatic or renal disease

Pruritus of hepatic disease and renal failure are difficult to treat. Management is primarily focused on the treatment of the underlying symptoms such as pain and itching. Several treatment options are

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

currently used, and UVB phototherapy has become widely accepted as an important tool in the management of these conditions (Wang, 2010).

Psoriasis

Koek and colleagues (2009) conducted a randomized controlled single-blind trial comparing office-based UVB treatment with home therapy for individuals with plaque or guttate psoriasis. This study involved 196 subjects who were evaluated through the initial therapy, with the first 105 subjects followed for an additional 12 months post-treatment. The authors reported that both treatments provided significant improvement from baseline, with home therapy being non-inferior to office-based treatment as measured by the psoriasis area and severity index (PASI) and the self-administered psoriasis area and severity index (SAPASI). No significant differences between groups were reported with regard to total cumulative radiation dose or short-term side effects.

Unrue and colleagues (2019) conducted a multicenter, prospective, open-label, interventional study to assess the treatment efficacy, adherence, and satisfaction of an ultraviolet home phototherapy system. The study included 8 participants with stable plaque psoriasis. Matched control and study lesions were assessed on each participant. All participants that completed the 10-week study experienced an improvement in the treated lesions with a mean improvement of 57% in Psoriasis Severity Index (PSI; $p < 0.0001$ compared to baseline, and $p < 0.0002$ compared to the control lesions). Control lesions did not significantly change in PSI over the study period with a mean change of 9% ($p = 0.1411$). No adverse events were reported. Participant treatment adherence was 96%. The results indicate that the home phototherapy system was a safe and effective monotherapy to manage plaque psoriasis in this group of participants.

The Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy (2019) included the following recommendation:

Recommend No. 1.8

Home NB-UVB phototherapy is recommended for appropriate patients with generalized plaque psoriasis as an alternative to in-office NB-UVB phototherapy. (Strength of recommendation: B; Level of evidence: I)

In 2022, Cohen and colleagues performed a systematic review of the use of home-based devices for the treatment of skin conditions. A total of 4 RCTs evaluating home UVB phototherapy for psoriasis

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

were included (Franken, 2015; Koek, 2009; Paul, 1983; Unrue, 2019). Conflicting evidence was identified for the efficacy of home-based UVB compared to traditional clinic-based administration. Three studies reported either significant improvements in PASI or PSI scores with home UVB use compared to controls, or non-inferiority of home therapy to office-based treatment. However, a study by Paul and colleagues (1983) showed the opposite outcome: while 90% of subjects who were treated in a clinic with phototherapy experienced complete clearance of psoriasis lesions, only 40% of subjects treated at home achieved the same result. Similar to the American Academy of Dermatology – National Psoriasis Foundation guidelines, the review gave a grade of recommendation of B for home phototherapy (UVB) devices for psoriasis.

Vitiligo

In 2021, Ashraf and colleagues published the results of a systematic review of three RCTs addressing home-based phototherapy for vitiligo. Two studies compared home-based with institution-based phototherapy, and one study compared home-based phototherapy with placebo. A total of 195 participants were included. The primary outcome was effectiveness of home-based phototherapy in achieving repigmentation; secondary outcomes were adverse effects of treatment, relapse rates and cost comparisons of institution- vs. home-based phototherapy. Therapy regimes varied between studies with four different types of NB-UVB devices used. Variable rates of repigmentation were achieved across studies but there was no significant difference in repigmentation rates between the groups. Adherence to treatment schedules was significantly better in home-based groups although adverse effects were also significantly higher in groups with home-based treatment vs. institution-based treatment (5% vs. 0% and 26% vs. 10%; two trials, 166 participants; RR 4.69, 95% confidence interval [CI], 2.16–10.21; $p < 0.0001$). These adverse effects included excessive hyperpigmentation, blistering and enlargement of vitiligo patches. No data were reported on long-term maintenance of treatment benefits. The authors concluded that “data were insufficient to form conclusions on effectiveness” of home-based treatment and that it would be difficult to recommend home-based treatment in clinical practice due to the higher risk of adverse events.

Thomas and colleagues (2021) reported the results of the Home Interventions and Light therapy for the treatment of Vitiligo Trial (Hi-Light Vitiligo Trial), an RCT which evaluated the comparative safety and effectiveness of a topical corticosteroid (TCS) and handheld NB-UVB therapy for the management of active limited vitiligo. The trial compared TCS (mometasone furoate 0.1% ointment) alone, NB-UVB alone, and TCS combined with NB-UVB. The primary outcome was treatment success at 9 months at a target patch assessed using the participant-reported Vitiligo Noticeability

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

Scale. Target patch treatment success was noted in 17% (TCS alone), 22% (NB-UVB alone), and 27% (combination treatment) of participants. An adjusted between-group difference of 10.9% (95% CI, 1.0% to 20.9%; $p=0.032$; number needed to treat = 10) showed that combination treatment was superior to TCS alone. NB-UVB alone was not superior to TCS with an adjusted between-group difference of 5.2% (95% CI, 4.4% to 14.9%; $p=0.29$; number needed to treat = 19). Participants with greater than 75% adherence to treatment were more likely to achieve treatment success but experienced a loss of effects once treatment stopped. The results showed that combination therapy was more likely to produce improved treatment response. However, combination therapy was only successful in about one quarter of participants. Although 517 participants were randomized, primary outcome data was only available for 370 participants. Attrition rates were similar in all three treatment arms. Most attrition occurred in the first 3 months of follow-up. Many leaving the trial said they did so because they could not commit the time required for the treatment. The high attrition rate left this trial insufficiently powered to provide precise confidence limits for the outcomes.

In 2020, Liu and colleagues published the results of a randomized pilot trial to determine the efficacy and safety of narrowband UVB phototherapy at home compared to hospital management of limited new-onset vitiligo. A total of 100 individuals with new-onset vitiligo (< 3 months) and < 5% body surface area involvement were randomized to either a home-based or a hospital-based treatment group and administered UVB phototherapy 3 times a week. At study-end (8 weeks), home- and hospital-based treatment showed similar efficacy but the frequency of adverse events, such as painful erythema, burning, blistering, and excessive hyperpigmentation, were increased in the home-based cohort. The authors noted that some in the home cohort intentionally extended their treatments in an effort to increase efficacy and recommended that attention be paid to avoid overexposure.

A prospective cohort trial enrolled 94 individuals with non-segmental vitiligo to evaluate the efficacy and safety of home and outpatient narrowband UVB therapy. Over a period of 6 months, 48 participants received treatment at home while 46 received outpatient treatment. Primary outcomes included efficacy, quality of life and adverse events. Overall, results were similar at 6 months between groups with higher efficacy seen on some measures for the outpatient group (Zhang, 2019). Further investigation in the setting of a randomized trial is warranted to more firmly determine the benefits of NB-UVB as a home-treatment for non-segmental vitiligo.

Shan and colleagues (2014) published the results of UVB home phototherapy for vitiligo in a prospective uncontrolled trial ($n=93$). Treatments were administered 3 times each week at variable

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

dosages. Follow-up was conducted every 3 months up to 1 year to evaluate repigmentation and any complications. At 1 year of follow-up, 35 subjects (38%) achieved excellent repigmentation, 16 (17%) achieved good repigmentation, 15 (16%) showed moderate repigmentation, 16 (17%) had poor repigmentation, and 11 (12%) had no repigmentation. A total of 25 (27%) individuals discontinued treatment due to poor repigmentation. This study was hampered by several design limitations, including a lack of randomization, and lack of appropriate comparator groups.

Eleftheriadou (2014) conducted a pilot trial to determine the feasibility of conducting a multicenter RCT to assess the safety and effectiveness of home hand-held NB-UVB phototherapy compared with topical treatments for repigmentation of vitiligo. Results showed that a larger RCT evaluating home hand-held phototherapy is feasible and acceptable to participants and healthcare providers. This trial was not intended as an efficacy trial.

While there is increasing evidence supporting the benefits of home-based UVB phototherapy, this treatment has not been generally accepted as standard treatment for vitiligo.

UVA home therapy devices

The use of UVA as a home therapy has not been shown to be safe and effective when compared to the other alternatives, such as office or facility-based treatment UVA therapy or UVB therapy. The AAD (2014) notes that given the limited number of head-to-head trials, there is no definitive recommendation regarding which form of phototherapy is more effective. UVA therapy requires the concurrent use of photosensitizers, which greatly increase the risk of complications. UVB therapy does not involve the use of photosensitizers.

Supplemental Information/Definitions

Definitions

Atopic dermatitis: The most common of many types of eczema; atopic dermatitis is a skin disease characterized by areas of severe itching, redness, scaling, and loss of the surface of the skin; when the eruption has been present for a prolonged time, chronic changes occur due to the constant scratching and rubbing.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

Mycosis fungoides (Cutaneous T-cell lymphoma): A type of non-Hodgkin's lymphoma cancer that first appears on the skin.

Pityriasis lichenoides: A skin disorder of children and young adults that is characterized by a rash of unknown cause, which usually goes away on its own.

Plaque: A broad, raised area on the skin.

Pruritus: The medical term for itching.

Psoriasis: A genetic, systemic, inflammatory, chronic disorder, characterized by scaly, erythematous patches, papules, and plaques that are often pruritic (itchiness). It is commonly located over the surfaces of the elbows, knees, scalp, and around or in the ears, navel, genitals or buttocks, but may appear elsewhere. It can be altered by environmental factors and may be associated with other inflammatory disorders such as psoriatic arthritis, inflammatory bowel disease, and coronary artery disease. The major manifestation of psoriasis is chronic inflammation of the skin that may be disfiguring, painful and severely pruritic and may cause significant quality of life issues. Psoriasis is a chronic disease that waxes and wanes during an individual's lifetime, the severity of which changes by treatment initiation and cessation. Some individuals can undergo spontaneous remissions.

Vitiligo: A skin disorder that causes loss of pigmentation (skin color) in blotches. The disorder affects the skin on any part of the body, including the hair, inside of the mouth, and eyes.

Ultraviolet (UV) light: Also known as UV light. This is a form of light invisible to the human eye that naturally comes from the sun but can also be produced by artificial light sources such as tanning lamps. Three types of UV light exist: ultraviolet A (UVA), ultraviolet B (UVB), and ultraviolet C (UVC).

References

1. Ashraf AZ, Azurdia RM, Cohen SN. The effectiveness of home-based phototherapy for vitiligo: A systematic review of randomised controlled trials. *Photodermatol Photoimmunol Photomed.* 2022; 38(5):409-417.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

2. Cohen M, Austin E, Masub N, et al. Home-based devices in dermatology: a systematic review of safety and efficacy. *Arch Dermatol Res.* 2022; 314(3):239-246.
3. Eleftheriadou V, Thomas K, Ravenscroft J, et al. Feasibility, double-blind, randomized, placebo-controlled, multi-centre trial of hand-held NB-UVB phototherapy for the treatment of vitiligo at home (HI-Light trials: Home Intervention of Light Therapy). *Trials.* 2014; 15:51.
4. Franken SM, Witte B, Pavel S, Rustemeyer T. Psoriasis and daily low-emission phototherapy: effects on disease and vitamin D level. *Photodermatol Photoimmunol Photomed.* 2015; 31:83-89.
5. Hallaji Z, Barzegari M, Balighi K, et al. A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis. *Photodermatol Photoimmunol Photomed.* 2010; 26(1):10-15.
6. Hodak E, Pavlovsky L. Phototherapy of mycosis fungoides. *Dermatol Clin.* 2015; 33(4):697-702.
7. Hung R, Ungureanu S, Edwards C, et al. Home phototherapy for psoriasis: a review and update. *Clin Exp Dermatol.* 2015; 40(8):827-832.
8. Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. *Am J Clin Dermatol.* 2007; 8(1):29-36.
9. Kleinpenning MM, Smits T, Boezeman J, et al. Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens. *Br J Dermatol.* 2009; 161(6):1351-1356.
10. Koek MB, Buskens E, van Weelden H, et al. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomized controlled non-inferiority trial (PLUTO study). *BMJ.* 2009; 338:b1542.
11. Liu B, Sun Y, Song J, Wu Z. Home vs hospital narrowband UVB treatment by a hand-held unit for new-onset vitiligo: a pilot randomized controlled study. *Photodermatol Photoimmunol Photomed.* 2020; 36(1):14-20.
12. Nikolaou V, Sachlas A, Papadavid E, et al. Phototherapy as a first-line treatment for early-stage mycosis fungoides: The results of a large retrospective analysis. *Photodermatol Photoimmunol Photomed.* 2018; 34(5):307-313.
13. Paul BS, Stern RS, Parrish JA, Arndt KA. Low-intensity selective UV phototherapy. A clinical trial in outpatient therapy for psoriasis. *Arch Dermatol.* 1983; 119:122-124.
14. Poligone B, Heald P. Menus for managing patients with cutaneous T-cell lymphoma. *Semin Cutan Med Surg.* 2012; 31(1):25-32.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

15. Shan X, Wang C, Tian H, et al. Narrow-band ultraviolet B home phototherapy in vitiligo. *Indian J Dermatol Venereol Leprol.* 2014; 80(4):336-338.
16. Thomas KS, Batchelor JM, Akram P, et al. Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial. *Br J Dermatol.* 2021; 184(5):828-839.
17. Unrue EL, Cline A, Collins A, et al. Corrigendum: A novel ultraviolet B home phototherapy system: Efficacy, tolerability, adherence, and satisfaction. *Dermatol Online J.* 2019; 25(4). Erratum for: *Dermatol Online J.* 2019; 25(2).
18. Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease and Lymphoma. *Int J Dermatol.* 2010; 49(1):1-11.
19. Zhang L, Wang X, Chen S, et al. Comparison of efficacy and safety profile for home NB-UVB vs. outpatient NB-UVB in the treatment of non-segmental vitiligo: a prospective cohort study. *Photodermatol Photoimmunol Photomed.* 2019; 35(4):261-267.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Akdis CA, Akdis M, Bieber T, et al.; European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Group. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *Allergy.* 2006; 61(8):969-987.
2. Arkwright PD, Motala C, Subramanian H, et al.; Atopic Dermatitis Working Group of the Allergic Skin Diseases Committee of the AAAAI. Management of difficult-to-treat atopic dermatitis. *J Allergy Clin Immunol Pract.* 2013; 1(2):142-151.
3. Centers for Medicare and Medicaid Services. National Coverage Determinations. Available at: https://www.cms.gov/medicare-coverage-database/search.aspx?redirect=Y&from=Overview&list_type=ncd.
 - NCD for Treatment of Psoriasis. NCD #250.1. Effective date not available.
4. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. *J Am Acad Dermatol.* 2019; 81(3):775-804.
5. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. *Ann Allergy Asthma Immunol.* 2004; 93(3 Suppl 2):S1-S21.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol*. 2010; 62(1):114-135.
7. Mohammad TF, Al-Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. *J Am Acad Dermatol*. 2017; 76(5):879-888.
8. National Cancer Institute (NCI). Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®). Last modified February 24, 2023.
Available at: <https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq>.
9. NCCN Clinical Practice Guidelines in Oncology® (NCCN). © 2023 National Comprehensive Cancer Network, Inc. Primary Cutaneous Lymphoma. V1.2023. Revised January 5, 2023. For additional information: <http://www.nccn.org/index.asp>.
10. Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. *J Am Acad Dermatol*. 2016; 74(1):27-58.
11. Sidbury R, Davis DM, Cohen DE, et al.; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014; 71(2):327-349.
12. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. *Eur J Cancer*. 2006; 42(8):1014-1030.

Government Agency, Medical Society, and Other Authoritative Publications:

1. American Academy of Dermatology. Available at: <http://www.aad.org>.
2. National Center for Advancing Translational Sciences. Cutaneous T-cell lymphoma. Updated February 2023. Available at: <https://rarediseases.info.nih.gov/diseases/6226/cutaneous-t-cell-lymphoma>.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: <http://www.niams.nih.gov/>.
4. National Psoriasis Foundation. Available at: <http://www.psoriasis.org>.

Policy History

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

03/21/2002	Medical Policy Committee/ review
03/25/2002	Managed Care Advisory Council approval.
06/24/2002	Format revision. No substance change to policy
03/08/2004	Medical Director review
03/16/2004	Medical Policy Committee review. Format revision. Phototherapy medical policy deleted. Policy specific to ultraviolet light and laser treatment of skin conditions formulated.
03/29/2004	Managed Care Advisory Council approval
03/01/2005	Medical Director review
03/15/2005	Medical Policy Committee review
04/04/2005	Managed Care Advisory Council approval
11/02/2005	Medical Director review
11/15/2005	Medical Policy Committee review. Format revision. FDA approval information added. Updated coverage eligibility to include use of UVB in treatment of psoriasis.
01/26/2006	Quality Care Advisory Committee approval
05/03/2006	Medical Director Review
05/17/2006	Medical Policy Committee Review. UVB has been removed from policy.
04/04/2007	Medical Director review
04/18/2007	Medical Policy Committee approval. Coverage eligibility unchanged.
11/07/2007	Medical Director review
11/15/2007	Medical Policy Committee approval. Replaced policy including title changed from Ultraviolet Light, Including Laser Therapy, for Skin Conditions.
11/05/2008	Medical Director review
11/18/2008	Medical Policy Committee approval. Targeted phototherapy for the first line treatment of mild psoriasis and generalized psoriasis or psoriatic arthritis is now considered to be investigational.
11/12/2009	Medical Policy Committee approval
11/18/2009	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/04/2010	Medical Policy Committee review
11/16/2010	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2011	Medical Policy Committee review

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

11/16/2011	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/01/2012	Medical Policy Committee review
11/28/2012	Medical Policy Implementation Committee approval. Title changed from Targeted Phototherapy for Psoriasis to Light Therapy for Psoriasis. Added new eligible for coverage statement. "PUVA for the treatment of severe, disabling psoriasis, which is not responsive to other forms of conservative therapy (e.g., topical corticosteroids, coal/tar preparations, and ultraviolet light), is considered to be eligible for coverage."
11/07/2013	Medical Policy Committee review
11/20/2013	Medical Policy Implementation Committee approval. No change to coverage.
11/06/2014	Medical Policy Committee review
11/21/2014	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/29/2015	Medical Policy Committee review
11/16/2015	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2016	Medical Policy Committee review
11/16/2016	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
11/02/2017	Medical Policy Committee review
11/15/2017	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/08/2018	Medical Policy Committee review
11/21/2018	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/06/2019	Coding update
11/07/2019	Medical Policy Committee review
11/13/2019	Medical Policy Implementation Committee approval. Added "When Services May Be Eligible for Coverage" and a "When Services Are Not Medically Necessary" sections for home ultraviolet light box therapy.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

- 11/05/2020 Medical Policy Committee review
- 11/11/2020 Medical Policy Implementation Committee approval. Removed “box” from ultraviolet light box therapy to read ultraviolet light therapy in the eligible for coverage and not medically necessary statements. Coverage eligibility unchanged.
- 11/04/2021 Medical Policy Committee review
- 11/10/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 11/03/2022 Medical Policy Committee review
- 11/09/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 11/02/2023 Medical Policy Committee review
- 11/08/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 02/01/2024 Medical Policy Committee review
- 02/14/2024 Medical Policy Implementation Committee approval. Title changed from “Light therapy for Psoriasis” to “Ultraviolet Light Therapy Delivery Devices for Home Use“. Extensive revisions made to the policy.

Next Scheduled Review Date: 02/2025

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT,

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	Delete codes effective 05/01/2024: 96912, 96913, 96920, 96921, 96922
HCPCS	E0691, E0692, E0693, E0694
ICD-10 Diagnosis	C84.00-C84.09, C84.10-C84.19, C86.6, K73.0-K73.9, K74.00-K74.69, K75.0-K75.9, L20.0-L20.9, L29.0-L29.9, L40.0-L40.9, L41.0, L41.1, N03.0-N03.A, N18.1-N18.9

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with technology evaluation center(s);

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ultraviolet Light Therapy Delivery Devices for Home Use

Policy # 00131

Original Effective Date: 03/25/2002

Current Effective Date: 05/01/2024

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.